Home / Transcripts / Arvinas, Inc. (ARVN) · November 5, 2025

Arvinas, Inc. (ARVN) Earnings Call Transcript

November 5, 2025

NASDAQ US Health Care Pharmaceuticals earnings 65 min

Earnings Call Speaker Segments

Jeff Boyle executive
#1

Hello, everyone, and thanks for being with us today. We put out a press release this morning covering our financial results for the third quarter of 2025, and you can find it in the Investor and Media section on arvinas.com. On the line with us are John Houston, who serves as Arvinas' Chief Executive Officer, President and Chairperson; Noah Berkowitz, our Chief Medical Officer; Angela Cacace, our Chief Scientific Officer; and Andrew Saik, our Chief Financial Officer. Ahead of getting started, I want to note that remarks made today include forward-looking statements involving risks, uncertainties and assumptions, all of which are described in today's press release and in the company's recent filings with the U.S. Securities and Exchange Commission, and I encourage you to review those. What actually happens could differ materially from what we discuss on this call. A replay of this call, along with an updated corporate deck, will be posted in the Investor and Media section of our website; and with that, I'll hand things over to John. John?

John Houston executive
#2

Thank you, Jeff. Hello, everyone, and I appreciate you being with us this morning. As we noted in the third quarter earnings release that went out earlier today, the past few months have been active and highly productive for Arvinas, defined by important advances in our corporate efforts as well as our clinical development programs. Over this quarter, we shared notable updates on our pipeline and on making our organization more efficient, all intended to unlock value from our portfolio so we can bring benefits to patients and returns to shareholders. Our extensive pipeline offers numerous avenues for creating value as we strive to tackle the biggest pockets of serious unmet need in oncology and neurology. We are now at the start of a period rich in data, with several readouts from our early-stage clinical programs, such as the recent clinical findings for ARV-102, our LRRK2 degrader, and preclinical results for ARV-806, our KRAS G12D degrader. We additionally shared the initial preclinical results for ARV-027, our encouraging new clinical candidate aimed at polyglutamine-expanded androgen receptor, or polyQ-AR, which is the underlying driver of spinal bulbar muscular atrophy, or SBMA. Beyond that, we expect to present preclinical results for our BCL6 degrader, ARV-393, at the ASH Conference in December, and preclinical results for our novel HPK1 degrader, ARV-6723, later this week at the SITC Conference. Noah will also provide an encouraging update from our continuing Phase I monotherapy trial with ARV-393 later on in today's call. We have a solid history of turning encouraging preclinical findings into major clinical wins, thanks to a platform that has repeatedly demonstrated its adaptability and potential. We keep adding to that history with numerous ongoing and planned clinical trials in areas of high unmet need, a pipeline of high-value assets, a robust research engine, and cash reserves extending into the second half of 2028, which affords us both financial and strategic flexibility. In September, we stated that we and Pfizer will together choose a third party for the commercialization and possible additional development of vepdegestrant, with the aim of quickly getting it to patients, if approved. The new drug application for Vepdeg is presently being reviewed by the FDA, and the agency has set a PDUFA action date of June 5, 2026. We aim to have a partner secured ahead of that date to ensure that Vepdeg, if approved, is ready for launch as a potentially best-in-class therapeutic option for ER-positive/HER2-negative advanced breast cancer in the second-line ESR1 mutant setting of ARV-393. Noah?

Noah Berkowitz executive
#3

Appreciate it, John, and hello everybody on this morning's call. I want to kick things off by discussing ARV-102, which is our orally administered PROTAC LRRK2 degrader, built specifically so that it penetrates the brain. The excitement coming from key opinion leaders and investigators, particularly regarding the biomarker results we recently shared at MDS, has made us even more confident that this program is genuinely differentiated. Let me first provide some context regarding ARV-102's target and which potential diseases of interest have emerged. LRRK2 is a protein containing multiple domains, and it carries out 3 critical roles: kinase, GTPase, and scaffolding activities. Through these roles, it helps control endolysosomal trafficking. Whenever LRRK2 expression or its activity goes up, lysosomal function gets disrupted, which compromises the removal of aggregated pathologic proteins that would ordinarily be broken down via that pathway. By degrading LRRK2, we may be able to bring endolysosomal homeostasis back and deliver therapeutic benefit in conditions marked by lysosomal dysfunction. Whereas inhibitors merely block LRRK2's kinase activity on an intermittent basis, ARV-102 gets rid of the whole LRRK2 protein; that matters since all 3 key functions, and not solely kinase activity, could be tied to neuroinflammation and lysosome dysfunction. Heightened activity, scaffolding, and expression of LRRK2 have all been connected to the pathogenesis of neurological diseases, among them idiopathic Parkinson's disease, a common neurodegenerative condition, plus progressive supranuclear palsy, or PSP, a neurodegenerative disease that advances quickly and is usually fatal within 5 to 7 years of diagnosis. Our view is that removing all 3 functions of LRRK2 via PROTAC-mediated degradation could deliver deeper and longer-lasting therapeutic benefit compared with traditional inhibitors. At last month's MDS Conference, we were happy to present data from 2 ongoing Phase I clinical trials involving ARV-102: one among healthy volunteers and another among patients with Parkinson's disease. Single ascending and multiple dose portions were part of both trials. Across both trials, ARV-102 is generally well tolerated. In the healthy volunteer study, ARV-102 was well tolerated at single doses reaching 200 milligrams and at multiple daily doses reaching 80 milligrams, with no discontinuations caused by adverse events and no serious adverse events seen in the study population. In the Parkinson's disease study, single doses of ARV-102 at 50 milligrams or 200 milligrams were well tolerated, with only mild treatment-related adverse events that were generally tied to the lumbar puncture procedure, and no serious adverse events occurred. Pharmacokinetic data also looked excellent in both trials. ARV-102 showed dose-dependent PK both in the periphery and in the CSF, and the latter signals brain penetration; regarding pharmacodynamic effects among healthy volunteers, repeated daily dosing of ARV-102 produced LRRK2 reductions reaching 90% in peripheral blood mononuclear cells, or PBMCs, and beyond 50% in the CSF. Repeated daily doses of ARV-102 brought about lower concentrations of phospho-Rab10T73 in PBMCs as well as lower urine concentrations of BMP. Each of those serves as an important biomarker for modulation of the lysosomal pathway downstream of LRRK2. Among patients with Parkinson's, we demonstrated that single doses of ARV-102 produced median PBMC LRRK2 protein reductions of 86% at the 50-milligram dose and 97% at the 200-milligram dose. Maybe the most noteworthy finding of all: among healthy volunteers who received 80 milligrams of ARV-102 once per day across 14 days, an unbiased proteomic study of CSF revealed reductions in numerous lysosomal pathway markers, for instance GPNMB, plus neuroinflammatory microglial markers such as CD68. A proteomics analysis published not long ago demonstrated that this identical biomarker panel was raised in individuals with LRRK2-related Parkinson's disease. We know of inhibitor data demonstrating shifts in certain of these biomarkers, yet that occurred solely in Parkinson's disease patients and solely following a minimum of one month of therapy, enough to engage the intended disease pathway — whereas even among healthy volunteers, where these biomarkers would not be anticipated to be elevated, and following just 14 days of dosing, this constitutes direct proof that our approach is functioning as intended. Such a swift pathway biomarker reaction implies that our total protein degradation strategy might deliver best-in-class impact on the disease processes underneath, in contrast to inhibitors that target kinase alone. In aggregate, we think our data so far establish an extremely high bar and further reinforce our confidence in what ARV-102 may achieve. The multiple dose cohort of our Parkinson's patient trial continues, and we anticipate sharing data, among it CSF LRRK2 degradation data, at a medical conference during 2026. Additionally, we plan to launch a Phase Ib trial among PSP patients within the first half of 2026. Now I'll move on to ARV-393, our investigational oral PROTAC engineered to degrade B-cell lymphoma 6 protein, or BCL6. BCL6 is a transcription factor that had gone undrugged previously, a master regulator governing numerous cellular processes throughout B-cell development, encompassing proliferation, survival and apoptosis. Changes in BCL6 activity have been tied to oncogenic driving of several non-Hodgkin lymphoma subtypes, which makes it a compelling therapeutic target where initial clinical validation is starting to appear. Through iterative activity, ARV-393 degrades the BCL6 protein both potently and swiftly, something essential for surmounting its fast resynthesis rate and maintaining antitumor activity. In preclinical work, ARV-393 has demonstrated strong in-vitro potency along with in-vivo efficacy when used as a monotherapy; also, earlier in this year, we shared preclinical results revealing improved antitumor activity when ARV-393 was paired with 5 classes of small molecule inhibitors in models of aggressive diffuse large B-cell lymphoma, or DLBCL. Our plan for developing ARV-393 incorporates combination approaches in DLBCL. Furthermore, at the American Society of Hematology Annual Meeting taking place next month, we will share fresh preclinical findings demonstrating that ARV-393 can be combined with glofitamab, a CD20xCD3 bispecific antibody that is becoming an emerging standard of care for DLBCL. Degrading BCL6 could raise CD20 expression, offering a rationale to explore ARV-393 alongside CD20-targeted agents and in situations of low or lost CD20 expression; we plan to start a combination trial involving glofitamab next year and anticipate updating you as we advance. Now to our clinical progress up to this point: enrollment in our Phase I monotherapy trial is continuing. This trial is first-in-human dose escalation, and the predicted efficacious exposure level has not yet been reached. But today, I have good news to share: despite exposure levels sitting under what we'd expect to be efficacious, responses have already appeared among early cohorts for both B-cell and T-cell lymphomas. Beyond that, we're seeing signs of strong BCL6 degradation, and ARV-393's safety profile has allowed us to keep escalating the dose. These initial findings make us quite happy, and we think they point to a therapeutic benefit for ARV-393 that is both emerging and differentiated. We can't wait to present further data from the Phase I trial at a medical congress in 2026. With that, I'll hand things over now to Angela. Angela?

Angela Cacace executive
#4

Noah, thank you — and good morning to all of you. It's a pleasure to walk through strong preclinical results we shared not long ago, which deepen our conviction that we can bring forward differentiated therapies spanning both our oncology and neuroscience pipeline. Starting with ARV-806, a novel PROTAC degrader we designed to target KRAS G12D. This driver is a well-characterized oncogenic mutation tied to poor outcomes, and it resists standard approaches in a number of major tumor types — pancreatic, colorectal and non-small cell lung cancers among them. No targeted therapy has won approval for KRAS G12D to date. Back in October at the Triple Meeting, we presented preclinical findings underscoring ARV-806's high potency and its clear distinction from KRAS inhibitors as well as degraders now being tested in the clinic; that work revealed robust, dose-dependent antitumor activity, with regressions seen across preclinical models of cancers carrying KRAS G12D mutations. ARV-806 builds productive ternary complexes with both the on and off states of KRAS G12D, showing in vitro picomolar potency alongside near complete degradation and strong selectivity. Its antiproliferative effect comes in at roughly 25x that of KRAS inhibitors and the most advanced degrader in clinical development. Notably, one dose of ARV-806 drives durable degradation exceeding 90% lasting 7 days, with activity across pancreatic, colorectal and lung cancer models; we also shared early, highly encouraging preclinical results for our oral pan-KRAS degrader and can't wait to say more as that program moves ahead. Enrollment is moving quickly in a Phase I trial of ARV-806, a sign of strong investigator interest and of the major unmet need for effective KRAS-targeted options. We're eager to report initial clinical findings from that study next year. Last, a quick note on updates from 2 other promising programs you'll be hearing more about during 2026. First, at World Muscle in October, we presented exciting preclinical results for ARV-027, a PROTAC degrader built to go after polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle. This degrader is intended for patients living with spinal and bulbar muscular atrophy, or SBMA — a rare, genetically defined neuromuscular condition that has no approved treatments and a substantial unmet need. Second, this week at SITC, we're unveiling ARV-6723, the first of our immuno-oncology focused PROTAC degraders. ARV-6723 goes after HPK1, a negative regulator of T-cell signaling that drives immune suppression in the tumor microenvironment and may matter across many solid tumors. What our preclinical work has shown so far indicates that breaking down HPK1 produces biology distinct from HPK1 inhibitors and anti-PD-1 therapies. We expect to kick off first-in-human studies for ARV-027 and ARV-6723 during 2026. As those studies get underway, we're excited to give full updates on the unmet need in each disease, the rationale behind each high-impact target, and why we think our PROTAC degraders will prove to be highly differentiated therapies for patients. With that, I'll hand things to Andrew, who will take you through our quarterly financials.

Andrew Saik executive
#5

Thanks, Angela, and good morning to all of you. I'm glad to discuss the financial results from the third quarter, which closed on September 30, 2025, and to share more detail about our thinking on capital allocation, returning capital to shareholders, and our development plans. As a quick note, complete financial details for Q3 can be found in this morning's press release. To begin, I'll quickly review a few important financial points from the third quarter of 2025. When the quarter ended, our balance sheet showed approximately $787.6 million in cash, cash equivalents and marketable securities, compared with $1.04 billion on December 31, 2024. For the quarter that wrapped up on September 30, 2025, we brought in $41.9 million in revenue. During the same three-month window in 2024, that figure stood at $102.4 million. The drop of $60.5 million traces back to the Novartis License Agreement — a deal we inked in the second quarter of 2024, with revenue from it recognized all the way through the close of that year. Partially making up for the decline was a $20 million milestone payment from Novartis, booked this quarter under the very same agreement. On the G&A side, third-quarter expenses totaled $21 million, compared with $75.8 million a year earlier. We saw a drop of $54.8 million, and the main reasons were as follows: ending our lease at 101 College Street back in August 2024 accounted for $43.4 million of that decline; personnel and infrastructure-related costs went down by $7.3 million; and professional fees fell by $3.6 million. For the quarter, non-GAAP G&A totaled $14.6 million, whereas the prior year came in at $64.8 million. Turning to research and development, expenses reached $64.7 million during the third quarter, compared with $86.9 million for the same period of 2024. Several factors drove that $22.2 million reduction: the vepdeg program was down $5.4 million, the luxdeg program was down $4.7 million, and personnel expenses along with non-program-specific expenses decreased by $15.1 million — partially offset by a $4.3 million increase in the KRAS program. On a non-GAAP basis, R&D came to $56.9 million for the quarter, down from $73.2 million the quarter before. Non-GAAP expenses totaled $71.5 million this quarter. As we partner with Pfizer to wind down what we're spending on vepdeg, and once our cost-cutting initiatives are fully in place, we anticipate those expenses will continue to fall. Keeping our quarterly spend under $75 million is the target, and that should let us hold non-GAAP expenses under $300 million for fiscal year 2026. Back in September, we shared that our Board gave the go-ahead to buy back as much as $100 million of our outstanding common stock. The Board's decision to approve this buyback reflects its assurance about where we're headed over the long haul, along with its view that the market is currently pricing our stock below what our future prospects justify. By the close of September, roughly 2.56 million shares had been repurchased, with an average price of $7.91 per share. Our 10-Q contains the specifics of this repurchase program. At the same time, we announced further reductions in expenses, and those savings let us maintain the cash runway guidance we'd given before, keeping it valid through the later part of 2028. We remain committed to directing capital into the areas that will deliver the greatest benefit to shareholder value as several important catalysts draw near in the coming months. Beyond that, we'll keep examining methods for trimming expenses and boosting efficiency, all while staying aimed at our objective of advancing our highly promising early-stage pipeline; having said that, I'll now hand things over to John for his concluding thoughts. John?

John Houston executive
#6

Thank you, Andrew. Our attention remains on bringing forward novel and differentiated products for conditions where significant needs remain unmet. We carry out our work with scientific discipline while extending the successful record we've established, spanning discovery through clinical development and into collaborations; our pipeline runs deep, featuring numerous clinical candidates that can generate value near term, mid term and over the long run, along with the possibility of standing apart through therapies of critical importance to patients. Arvinas has reached a pivotal point in its growth journey. Across the remainder of this year and continuing into 2026, our clinical pipeline provides a substantial array of catalysts, with many studies expected to begin and data expected to be reported throughout our neuroscience and oncology franchises. Given that our PDUFA date is now set for next year, we are nearing a landmark occasion, one that could bring about the very first approval of our PROTAC therapy. We are strongly positioned to create considerable value for shareholders, for our partners and for the patients we serve; with that said, I'll hand things over to Jeff so the Q&A portion of this call can begin. Jeff?

Jeff Boyle executive
#7

Prior to handing things off to the operator, I'd like to request that everyone stick to a single question per round, so we can ensure each person gets adequate time. Afterward, you're welcome to get back in line to ask something further; so with that, operator, would you go ahead and open the line?

Etzer Darout analyst
#8

I have one quick item regarding the BCL6 degrader program. We are going to see updated data from <<inaudible>> at ASH. I wanted to ask — could you share your thoughts on the differentiation points they are pursuing <<inaudible>>, and could you also discuss a bit the dosing profile you have in mind for this molecule, plus any areas where that molecule might stand apart over a longer horizon?

John Houston executive
#9

Wonderful. Many thanks for bringing that up. Yes, our BCL6 program has us quite enthusiastic, and we genuinely think its profile will set it apart as development of the compound moves forward. Noah, would you like to offer a few remarks?

Noah Berkowitz executive
#10

Absolutely. Thank you, John, and I appreciate you asking that. Yes. So we do — and incidentally, your audio cut out somewhat, but if it concerned dosing — correct, and differentiation. The drug is administered orally once each day. There are a few distinct levels where differentiation matters. First, we have already shown, and will keep showing in the upcoming ASH presentation, what I'd call a differentiated profile for combos involving the drug, and even for single-agent treatment in preclinical work. Thus, we observed that complete responses can be reached across multiple models, in contrast to the tumor growth inhibition observed with certain competitor — yes, certain drugs from competitors. Regarding our program, we've stated quite clearly that our focus is monotherapy in AITL, and we're keen on building the combination with the bispecific for DLBCL. So currently, multiple competitors have come into the market. One — a single one among them has already shared data, while the rest appear to have only just submitted their IND; our belief is — and we've presented data here showing monotherapy activity in T-cell and B-cells. The competitor that has already reported some B-cell malignancy responses has not reported that. Therefore, that represents a possible differentiation point going forward.

Yigal Nochomovitz analyst
#11

Caroline here, filling in for Yigal. Regarding your LRRK2 program, could you describe the initial kinds of signals you would be watching for in the Parkinson's disease MAD Phase I? And what duration of dosing do you hypothesize is necessary for the PK effects already seen in healthy volunteers to translate into clinical benefit in Parkinson's patients?

John Houston executive
#12

Yes. No, thank you, Caroline. Excellent question, and I'll pass it over to Noah.

Noah Berkowitz executive
#13

Appreciate it, John and Caroline. And thanks for asking. So yes, what we've observed so far with our LRRK2 degrader has us quite enthusiastic, and the response we got at a conference recently at MDS as well. As you mentioned, we're right now advancing fairly aggressively through a Phase I study in Parkinson's disease involving 28 days of dosing. The data we expect out of this will mostly relate to biomarkers. That said, we might begin gathering a bit of clinical efficacy data too, which isn't something you'd anticipate with 28 days of dosing. What we've already communicated is that we've managed to show pathway engagement in ways that rival LRRK2 inhibitors have not — or at least have not yet reported. So we know that in healthy volunteers, we're able to affect endolysosomal trafficking as well as neuroinflammation, at least via microglial pathways — mediated pathways. And so when we now examine our Parkinson's disease patients, the thinking is that we have patients at baseline whose LRRK2 levels in their CSF are more than 2, perhaps even 3x the baseline level. These pathways are far more activated; and it will matter to see how much of the degradation we've already reported in healthy volunteers we can now recapitulate in this Parkinson's disease population, and to look at that pathway engagement. So we've guided toward an update on those pathway markers next year, fairly early next year; and — though I believe the next step when it comes to clinical data will arrive once we can treat for more than 28 days; so toward that end, we're making our way through the chronic tox study. And so you'll see, as we file our IND next year that lets us move into PSP, that we're ready to keep treating patients chronically, and that will give us a chance to show clinical benefits in diseases such as PSP and potentially Parkinson's.

Michael Schmidt analyst
#14

This is Sarah, filling in for Michael. I just had a question about your KRAS G12D. You've brought this up previously, and we've observed proof that KRAS amplification acts as a resistance mechanism against inhibitors. So — and the reality that possibly, given a PROTAC's iterative activity, it could get past that; so I simply wanted to check whether you have any intentions to potentially study ARV-806 or perhaps down the line a pan-KRAS in the clinic within a KRAS amplified population.

John Houston executive
#15

Yes. Excellent questions, Sarah. I'll have Angela Cacace, our CSO, along with Noah each provide you 2 parts to that answer.

Angela Cacace executive
#16

Appreciate that. Thanks for asking. We've definitely been examining our G12D degrader, ARV-806, in the resistant setting. What we observe is amplification of KRAS G12D, and we find that under every condition we suppress KRAS durably. Then, regarding our pan-KRAS degrader, we've likewise been investigating the amplified setting — specifically wild-type amplification. In that wild-type amplified context, we're pleased that some early data reveals quite attractive tumor growth inhibition; and with PDX models, regression has also been observed. So our pan-KRAS degrader program is moving ahead quite rapidly, and I'll hand things to Noah for the clinical view.

Noah Berkowitz executive
#17

Thank you, Angela. And Sarah, regarding your question about amplification and the observations we've made. In our ongoing Phase I trial, we deliberately exclude patients who have previously received KRAS inhibitors. As a result, that's not a scenario we anticipate encountering during the dose escalation phase of our study, and it makes sense why we'd seek the clearest possible signal; that decision was made just as anyone would make it. However, what we've come to understand during the last 12 months — and this is largely from data produced outside our organization — is that numerous reports indicate amplification serves as a key resistance mechanism following exposure to KRAS inhibitors. So we have, as Angela mentioned, conducted work with our models demonstrating that this presents a significant opportunity going forward. We anticipate providing some updates at some point within the coming year regarding whether we choose to broaden our targeting or our thinking on this matter; the science here is certainly compelling.

Derek Archila analyst
#18

Hal here, filling in for Derek at Wells Fargo. So I suppose we've got something to ask regarding ARV-102. Regarding the SAD data, are you observing any LRRK2 degradation in CSF? And then, for the MAD data coming next year in 2026, I just wanted to check whether you have any expectations. Is it that more than 50% in healthy volunteers you were looking to replicate, or simply some expectation for us to frame?

John Houston executive
#19

Thanks for asking. Of course. So Noah, would you like to handle that?

Noah Berkowitz executive
#20

Right, of course. So, though I believe our guidance already points toward this. Basically, once we finish the MAD portion in patients with Parkinson's disease, we'll share our LRRK2 degradation data. And that's pretty much what we're steering toward for next year.

Jeet Mukherjee analyst
#21

Let's turn back to ARV-806. Drawing on what you've learned from other G12D inhibitors and degraders currently being developed, is there anything at the molecular level—any features or attributes—that could be tied to or associated with the GI tolerability issues and raised liver enzymes observed with certain of these molecules? And if so, is ARV-806 designed to steer clear of those features?

John Houston executive
#22

Yes. Appreciate the question. I'd say without a doubt, the — our G12D compound has a profile that's really exciting. Clearly, this molecule differs from other G12D inhibitors. Angela, perhaps you could speak to what you believe are some of the kinds of features that produce the profile we're seeing?

Angela Cacace executive
#23

Alright. So, as we've outlined, from a molecular standpoint our ARV-806 G12D PROTAC genuinely possesses some quite attractive attributes. It attaches to the on-state as well as the off-state, and it's 25x more potent than every mechanism currently in the clinic that we have tested up to now. Yet in light of what we've observed with the clinical degrader, we're additionally several orders of magnitude more potent when it comes to engaging the target and degrading it durably. So keeping that in mind, we anticipate greater potency, which ought to translate clinically. And I'll let Noah go ahead and take the liver and other questions.

Noah Berkowitz executive
#24

Yeah, so at this point, I'd say what we're doing there, grounded in the science we have, is aiming to come out ahead on potency. What I mean is, we already know from a competitor's degrader that transaminitis showed up and held them back from raising their dose. So because we're able to engage our target at concentrations that are much lower, that points to a potential where we don't hit those kinds of toxicities and still achieve the meaningful degradation we're after. What we're targeting, then, is degradation of our target above 80%. It's quite possible we could do considerably better than that. And as we move through our dose escalation cohorts, we'll give updates along the way.

Sudan Loganathan analyst
#25

Keith Alve here, speaking for Sudan. I have a quick question about ARV-806. Are you looking into how degrading KRAS G12D through PROTAC therapy could either work alongside or differ from combos such as the cetuximab pairing observed with the KRAS12 G12D inhibitor from Verastem?

Angela Cacace executive
#26

Yeah. In preclinical work, we've looked at pairing it with anti-EGFR inhibitors, cetuximab included; we see that as a significant plus since our method of degrading G12D KRAS is selective. In that scenario, the combination performs very well, and within the year we'll share the preclinical data we've produced from those combinations. Noah?

Noah Berkowitz executive
#27

And yes, I would simply mention that evidence is certainly building that pairings of inhibitors alongside chemotherapy—and, as you brought up, with an EGFR inhibitor too—can result in cumulative tox that might prove limiting for this drug, yet for this group of inhibitors, that opens a door for us, particularly, correct? Since, returning to that potency point, if our drug can be brought into play, which at present calls for weekly—once-a-week administration and could eventually let us reach dosing once every 2 weeks as well, and we can accomplish that at lower dosing—reduced doses, and we may avoid the same kind of cut tox from combinations, that unlocks an entire array of chances to produce a better benefit risk profile; so, once more, we must complete our monotherapy dosing. It's progressing very quickly. And we're hoping to enter our combinations next year already, though more will follow on that.

Angela Cacace executive
#28

Let me quickly note as well that going after the pan-KRAS mechanism presents a difficulty within that combination context, mostly since those agents are also targeting HRAS. That turns into a significant hurdle when you try to layer in a mechanism built on EGFR; our KRAS G12D degrader, then, would sidestep that problem.

Tyler Van Buren analyst
#29

Francis here, filling in for Tyler. Regarding the BCL6 asset, which combination partners strike you as the most exciting? And assuming it gets developed successfully, where do you see it most likely fitting within the lymphoma treatment paradigm?

John Houston executive
#30

Appreciate the question. Sure, BCL6 offers a great many combinations that could prove exciting. I'll turn it over to Noah, who can perhaps walk through our current thinking.

Noah Berkowitz executive
#31

Right. So we've provided information regarding how this drug can be paired, and it takes a different mechanistic route compared to a lot of the treatments that have gotten approval for B-cell malignancies at present. And what we observe is simply gorgeous synergy and the capacity to combine it — in preclinical work with EZH2 inhibitors, BTK inhibitors, BCL2 inhibitors, plus anti-CD20 agents as well. So that represents an entire array of chances for combining; we understand that given how this area is developing, bispecifics aimed at CD20 are going to play a notably outsized part in the — ultimately the frontline setting, yet in the second- and third-line setting too for large B-cell lymphoma; we believe that is our — as an organization we want to stay extremely focused, and we understand that represents a major opening where we can bring together these treatments that possess toxicities that don't overlap. Ours — the initial step is to determine a toxicity. But clearly, CRS occurs with the bispecifics, and we ought to be able to pair them in a favorable way. And that would be our intention. That's the reason we've stated that in the coming year, we anticipate advancing our Phase I trial with combinations involving bispecifics.

Li Watsek analyst
#32

I've got a strategy question; it seems like you're shifting additional programs toward the preclinical and clinical stages, and perhaps strengthening what you're doing in the neuromuscular area while also branching out into I-O; so I'm just wondering, first, what your BD strategy looks like here, considering you have 5 programs. And second, how you think about allocating resources.

John Houston executive
#33

Yeah; thanks for asking. It's clear that over the last several months, the company has undergone a major reset, and obviously, the choice we made together with Pfizer to seek a new partner or out-license vepdegestrant let us concentrate on the remainder of our pipeline. And obviously, KRAS G12D, LRRK2, BCL6 are the next assets in line that are in Phase I and moving quite quickly toward Phase II. And then behind those we have 2 programs that ought to reach the clinic fairly soon: one in SDMA, which we can discuss, and the other HPK1, which is an I-O. And we think that provides us with a range of different programs spanning oncology and neuro; and yes, HPK1 holds enormous potential in immuno-oncology. So that's something we're excited about. It hands us a great deal of flexibility; it hands us a great deal of choice. And as has always been true throughout — the entire history of Arvinas, those choices have also encompassed suitable and well-placed BD opportunities. So we'll remain open to that at all times. We believe some of our targets truly lend themselves to BD opportunities. And at this moment, as things stand today, our entire portfolio is fully owned by our vepdegestrant, and we did complete a significant deal with Novartis on luxdegalutamide. So yes, we proceed with a great deal of confidence, and we have some truly excellent, exciting data that ought to emerge over the coming several months and year, and we'll be able to position our portfolio in the best manner we can; and that might involve selective partnering.

Srikripa Devarakonda analyst
#34

Perhaps I could ask something that builds on what was just discussed. You've got close to $800 million in cash, and that gives you runway into the second half of '28 — and I don't just mean how far the calendar stretches, but which studies that money can actually carry you through, which would be useful to know. And then, as the pipeline moves ahead, are you still going to pursue PROTACs in oncology as well as CNS? Or do you feel that at this stage, you need to pick a priority based on therapeutic area?

John Houston executive
#35

Appreciate the question. For the first part of it, I'll definitely pass things to Andrew, our CFO. On the second part, though — yes, this company has been focused on oncology since day one, and I believe the third target we ever worked on happened to be in neuroscience. So neuroscience has been part of what we do from the very start of the company. Our view is that PROTACs, and specifically the capability to make brain penetrant PROTACs, offer an enormous potential edge when it comes to neurodegenerative diseases. That's something we intend to pursue as we move ahead with programs such as LRRK2; we're also quite enthusiastic about now examining a neuromuscular target like SBMA. And we remain convinced there's substantial differentiation for us in oncology; so even if that sounds like 2 therapeutic areas that are wildly different, the knowledge we gain and what PROTACs let us do in each of them, I believe, opens up a great deal of differentiated opportunity; so for the time being, we'll keep going down that path. Other opportunities are something we're open to and always on the lookout for; but as of right now — and here I'll turn it to Andrew — we're in a strong position to fund the programs we have, particularly following the reset we carried out. Andrew?

Andrew Saik executive
#36

Right. Thank you, John. So how I view allocating capital over at minimum the coming 12 to 24 months — for the past several years this company has put a lot of money into the vepdegestrant Phase III trials. Those expenses are going to begin declining. What will take their place is a group of Phase I early-stage studies, correct? So essentially we are placing a wager on the early-stage programs. We are very fond of them. At this moment, clearly, we cannot say which of them we will advance on our own and which we will end up licensing. Every one of them will get our effort. In our view, a great many of them are extremely, extremely promising; and as we move through the development pipeline, we will be making calls on them. So we examine these programs across their full trajectory. Naturally, our programs have been familiar to us for quite a while; thus they were already part of our spending well before we said they would be entering the clinic. So none of this caught us off guard; and we are simply thrilled; so we will keep driving forward on our Phase I programs, and as we progress we will decide based on which ones we believe it makes the most sense for us to retain and which ones it makes the most sense for us to potentially partner.

Tazeen Ahmad analyst
#37

Regarding 102 specifically, with the biomarker data you currently have on hand, how should we think about how well those translate into clinical endpoints for PD? And then I'd also like to understand, once the PD results are shown in 2026, where do you expect your attention will be directed so that you can back the move forward into a Phase Ib trial in PSP?

John Houston executive
#38

Thanks. That's a good question. Noah?

Noah Berkowitz executive
#39

Absolutely. Thank you, John, and it's great to hear from you, Tazeen. So, yeah, 102 — for us this is simply a thrilling story, because to recap and extend on what John and Andrew were just saying, if you look back, we've had programs in oncology, and we've also been building in neuroscience. And now here we are, right after a successful registrational trial for VEP-2, the out-licensing to Novartis of luxdegalutamide, which is an AR degrader, and we're pushing forward 2 oncology drugs. And at this point, we now have ARV-102, where we recently shared some remarkable data that push us toward PSP and potentially Parkinson's disease. So for a long stretch — across many years now — enormous resources have gone into the Parkinson's disease community and the PSP community to figure out which pathways are responsible for driving this neurodegenerative illness. And there's a big biomarker study known as PPMI, which examines how Parkinson's disease naturally progresses. And it has shown that certain markers exist, like GPNMB, IAB1 — IBA1 — and CD68 as well, plus a group of cathepsins. These are markers that predict how the disease will progress, since they push neuroinflammation and they also push neurodegeneration, which happens because proteins get mistrafficked. That comes down to endolysosomal function. All of these markers are elevated when the disease is present. And we just presented a study at MDS that generated enormous enthusiasm among investigators, and among scientists more broadly, because we demonstrated that in healthy volunteers, we could lower these biomarkers, correct? And now we're conducting the Parkinson's disease study, which is examining all of these biomarkers, and we anticipate that if we degrade LRRK2 to the degree we observed in healthy volunteers — where we hit 75% reduction, which is more than sufficient to move this into PSP and PD studies — we ought to be able to push down those biomarkers responsible for neuroinflammation and for mistrafficking of proteins like tau. So, with that as a foundation, we have the healthy volunteer data. We're going to report our Parkinson's disease data on LRRK2 degradation and biomarkers. And then the following year, if all goes well, launch a PSP study. PSP is a neurodegenerative condition that likewise depends on this mistrafficking of tau, and we know our drug is able to fix that mistrafficking. It can improve the — reduce the neuroinflammation that also sits at a root cause of PSP. And we'll treat patients on a continuous basis, meaning it's no longer capped at 28 days, and keep gathering biomarker data and tie that to clinical measures such as PSPRS and others. And we hope to report the results of that Phase Ib study shortly. And if all goes well, we might begin a Phase II study even before that Phase Ib study has finished. So, a registration-quality Phase II study. But precisely when that can begin is something we have to wait on, until we clear our IND and get the Phase Ib study started.

Angela Cacace executive
#40

Also, to expand on that point, we're aware that human genetics indicate LRRK2, and as Noah mentioned, LRRK2 levels are raised in microglia within the brains of idiopathic Parkinson's disease patients. Additionally, in progressive supranuclear palsy, the very same SNPs that raise LRRK2 also cause faster progression in a clinically meaningful manner as well as a shorter time to death. Therefore, by approaching this with a clear method to modulate the LRRK2 pathway, we believe we have the greatest opportunity to confirm the LRRK2 hypothesis in disease, both in progressive supranuclear palsy and possibly in Parkinson's disease.

Paul Choi analyst
#41

What I'd like to know is whether there are any extra dosing cohorts for ARV-393 that could show up at the ASH Meeting that's coming up, and whether some of those might land in the target therapeutic range you're going after. Then, regarding ARV-027, I'm wondering whether you've considered other CAG repeat related diseases as possible areas to look into, Huntington's included, or other neuromuscular diseases, not just the spinal cerebellar ones you started with.

John Houston executive
#42

Yes. Thanks. Those are probably things Noah and Angela can address.

Noah Berkowitz executive
#43

Okay, addressing the first inquiry about ARV-393, we've provided specific direction on this. Ideally, we'd have been in a position to deliver a complete update at ASH this year regarding dose escalation for ARV-393. However, the reality is we haven't yet reached what we expected — or forecast — would be the efficacious range, even though, quite remarkably and very encouragingly based on our data, we're observing responses, meaningful responses, CRs even in T-cell and B-cell malignancies. So reporting merely what we're seeing at low dose levels doesn't strike us as wise. Typically, a study would want to present results once you're confident you're fully hitting your target and could demonstrate the drug's complete robustness. That would be the right moment. Still, we definitely didn't want to leave you — leave people waiting. So we aimed to convey that progress is happening, and we're witnessing both efficacy and tolerability from the drug. As for the 027 question, I'll hand that over to Angela.

Angela Cacace executive
#44

Alright, thanks. For 027, what drew us to it was its distinctive ability to break down the polyglutamine repeat androgen receptor both inside the nucleus and out in the cytoplasm — and that matters a great deal since it's a key disease driver in spinal and bulbar muscular atrophy. We've shared some highly encouraging results demonstrating that we restore muscle function, such as grip strength and endurance, all the way to the endpoints that matter most for people living with this condition. So that represents a really promising opportunity. When it comes to disorders caused by polyglutamine repeat expansions, we've got a strong strategy in place; that's the path we're pursuing for these repeat disorders. Huntington's disease is getting a dual strategy from us as well; in that case, we've found selective ligands that target mutant Huntington while leaving wild type untouched; so our work continues. We're at an early stage, yet things are moving along nicely; beyond that, the whole notion of going after repeat expansion disorders is something we treat with real seriousness, and we see a highly distinctive opening in that area too. So it's early, but it's a really thrilling space for Arvinas.

Noah Berkowitz executive
#45

If I may add one more point to what was just said. So, as we enter the SBMA program, the first step is healthy volunteers, which is the right approach. What makes this such a strong opportunity is that the condition is essentially monogenic. The target is completely clear to us: polyQ-AR. And we've established that degradation of it is achievable, so with healthy volunteers we will also be able, should permission be granted, to perform muscle biopsies, and that will provide very rapid validation for this technology. That makes it an ideal situation for us to move into a rare disease area, since we can obtain results and gain confidence regarding pathway engagement through healthy volunteer studies, which is not something you often get.

Jon Miller analyst
#46

Congratulations on everything you've accomplished so far with the early pipeline. If I could, I'd like to begin with the KRAS combinations. You brought up a few interesting possible combination partners for the KRAS program — things that other companies in this area may have struggled to pair with because of the tolerability profile. How soon might we be able to enter combo cohorts? Could that be something we'd see even in expansion cohorts beginning next year? Or should we assume that rituximab combos and things beyond that might come somewhat later than that? Then second, regarding the HPK1 program, it clearly still seems quite early, but it could be pretty interesting. I saw that there wasn't much on the deck about it. When do you think you'll show us additional preclinical data and give us a sense of which indications might be the most fruitful to look at early on?

John Houston executive
#47

Those are great questions, and I'll rely on my usual double act of Noah and Angela to address them.

Noah Berkowitz executive
#48

Appreciate that, John, and I appreciate the question. Sure, so regarding the 806 question, we aren't providing guidance at this point on when the combination will happen. That means anything I say would be guesswork on my end, though I do enjoy guessing. The key point is that at this moment we are moving very quickly through our dose escalation, since there's enormous interest in this, and it appears to be tolerable for patients. So the thinking is that we intend to move into that combination right away after we complete some — we don't even need to hold off until our expansions have fully read out. We could kick that off sooner. So if everything moves really quickly, we're hopeful it might be something we could begin next year, but I can't give guidance; everything depends on the clinical data, correct? That's definitely a possibility.

Angela Cacace executive
#49

All right. Then you moved on to asking about ARV-6723, which is our HPK1 degrader. We couldn't be more enthusiastic regarding what this degrader might do. Its profile differs quite a bit from PD-1 as well as from the HPK kinase inhibitor — the kinase inhibitor of HPK that doctors are already using in trials. What we've managed to demonstrate, and what will be presented at SITC, concerns the effect on T-cell exhaustion and, just as important, the effect on the T-cell microenvironment. The changes we're observing there are striking, and in both tumor models with low immunogenicity and those with high immunogenicity, we beat anti-PD-1 and HPK1 inhibitors in preclinical work. So keep watching. There's much more coming about our oral immunotherapy, which we believe will beat the competition and prove quite valuable when checkpoint blockade no longer works. That asset has all of us pretty fired up.

Andrew Berens analyst
#50

Amanda here, filling in for Andy. What we're trying to find out is what you've discovered regarding drug-drug interactions with vepdeg that makes you confident you won't run into comparable interactions with the new degraders. I mean, whether there's something <<inaudible>> possesses, or the way they get metabolized along similar or different pathways.

John Houston executive
#51

Yes, thanks for asking. Generally speaking, when it comes to analyzing them for DDIs, PROTACs aren't any different than small molecules. Each molecule is unique; they're metabolized in distinct ways; they engage with other molecules in distinct ways; so you can't give a one-size-fits-all answer about PROTACs, since every individual PROTAC will be unique and distinct. So yes, with certain compounds, as with many drugs, you examine how they're metabolized to determine whether a drug-drug interaction exists, and you may observe some of that, or you may not; that's precisely what we're observing with PROTAC. So a PROTAC's DDI potential is no different from that of any small molecule.

John Houston executive
#52

Okay, I really appreciate it, and I appreciate all the excellent questions from everyone. As you can probably tell, we're quite enthusiastic regarding this upcoming set of programs moving through our early development pipeline, and we'll be glad to share additional details with you over the next few months; there's a great deal of compelling data that will be released. So once more, thank you for spending your time with us.

Operator operator
#53

Everyone, that brings us to the end of today's call. Thanks to each of you for being with us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arvinas, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arvinas, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.